These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32825118)

  • 1. Trichostatin A Alleviates Renal Interstitial Fibrosis Through Modulation of the M2 Macrophage Subpopulation.
    Tseng WC; Tsai MT; Chen NJ; Tarng DC
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
    Pang M; Kothapally J; Mao H; Tolbert E; Ponnusamy M; Chin YE; Zhuang S
    Am J Physiol Renal Physiol; 2009 Oct; 297(4):F996-F1005. PubMed ID: 19640900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury.
    Marumo T; Hishikawa K; Yoshikawa M; Hirahashi J; Kawachi S; Fujita T
    Am J Physiol Renal Physiol; 2010 Jan; 298(1):F133-41. PubMed ID: 19906951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis.
    Cui SN; Chen ZY; Yang XB; Chen L; Yang YY; Pan SW; Wang YX; Xu JQ; Zhou T; Xiao HR; Qin L; Yuan SY; Shang Y
    Int Immunopharmacol; 2019 Dec; 77():105973. PubMed ID: 31677992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H
    Zhou Y; Zhu X; Wang X; Peng Y; Du J; Yin H; Yang H; Ni X; Zhang W
    Exp Cell Res; 2020 Feb; 387(1):111779. PubMed ID: 31846625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of IL-18 reduces renal fibrosis after ischemia-reperfusion.
    Liang H; Xu F; Zhang T; Huang J; Guan Q; Wang H; Huang Q
    Biomed Pharmacother; 2018 Oct; 106():879-889. PubMed ID: 30119258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis.
    Van Beneden K; Geers C; Pauwels M; Mannaerts I; Wissing KM; Van den Branden C; van Grunsven LA
    Toxicol Appl Pharmacol; 2013 Sep; 271(2):276-84. PubMed ID: 23707763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
    Rahman MM; Kukita A; Kukita T; Shobuike T; Nakamura T; Kohashi O
    Blood; 2003 May; 101(9):3451-9. PubMed ID: 12511413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jmjd3/IRF4 axis aggravates myeloid fibroblast activation and m2 macrophage to myofibroblast transition in renal fibrosis.
    Liang H; Liu B; Gao Y; Nie J; Feng S; Yu W; Wen S; Su X
    Front Immunol; 2022; 13():978262. PubMed ID: 36159833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages.
    Han SB; Lee JK
    Arch Pharm Res; 2009 Apr; 32(4):613-24. PubMed ID: 19407980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF-1R inhibition attenuates ischemia-induced renal injury and fibrosis by reducing Ly6C
    Deng X; Yang Q; Wang Y; Zhou C; Guo Y; Hu Z; Liao W; Xu G; Zeng R
    Int Immunopharmacol; 2020 Nov; 88():106854. PubMed ID: 32771945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy.
    Wang D; Xiong M; Chen C; Du L; Liu Z; Shi Y; Zhang M; Gong J; Song X; Xiang R; Liu E; Tan X
    Kidney Int; 2018 Jul; 94(1):91-101. PubMed ID: 29656902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trichostatin A Ameliorates Conjunctival Fibrosis in a Rat Trabeculectomy Model.
    Sung MS; Eom GH; Kim SJ; Kim SY; Heo H; Park SW
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3115-3123. PubMed ID: 30025124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis.
    Zhang Y; Zou J; Tolbert E; Zhao TC; Bayliss G; Zhuang S
    FASEB J; 2020 Jun; 34(6):7295-7310. PubMed ID: 32281211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
    Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo.
    Ota C; Yamada M; Fujino N; Motohashi H; Tando Y; Takei Y; Suzuki T; Takahashi T; Kamata S; Makiguchi T; Yamaya M; Kubo H
    Exp Lung Res; 2015; 41(8):422-34. PubMed ID: 26151196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage-to-Myofibroblast Transition Contributes to Interstitial Fibrosis in Chronic Renal Allograft Injury.
    Wang YY; Jiang H; Pan J; Huang XR; Wang YC; Huang HF; To KF; Nikolic-Paterson DJ; Lan HY; Chen JH
    J Am Soc Nephrol; 2017 Jul; 28(7):2053-2067. PubMed ID: 28209809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis.
    Ding H; Jiang L; Xu J; Bai F; Zhou Y; Yuan Q; Luo J; Zen K; Yang J
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F561-F575. PubMed ID: 28228400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
    Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
    Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen-like protein 2 deficiency aggravates renal fibrosis by facilitating macrophage polarization.
    Wu S; Li M; Xu F; Li GQ; Han B; He XD; Li SJ; He QH; Lai XY; Zhou S; Zheng QY; Guo B; Chen J; Zhang KQ; Xu GL
    Biomed Pharmacother; 2020 Oct; 130():110468. PubMed ID: 32795921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.